The Victoza market in Australia is experiencing steady growth, supported by a strong public healthcare system, high awareness of diabetes management, and favorable reimbursement frameworks. Increasing obesity rates and type 2 diabetes prevalence are major drivers, along with physician preference for clinically validated GLP‑1 therapies. However, the entry of newer, longer-acting GLP‑1 drugs poses a restraint to Victoza’s growth. Opportunities lie in expanding indications and digital patient engagement tools. A growing trend is the integration of Victoza into personalized treatment plans involving mobile health platforms. The Victoza market in Australia is estimated to grow at a CAGR of approximately 6.7%.
TABLE - Australia Victoza Market Size & Forecast By Indication 2021-2033
Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type 2 Diabetes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Obesity Management (Off-Label Use) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Australia Victoza Market Size & Forecast By Distribution Channel 2021-2033
Distribution Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Retail Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Online Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis